Alector (ALEC) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alector (ALEC) has outperformed Compass Therapeutics (CMPX) over the past year, losing 37.5% versus a loss of 71.7%. Over five years, CMPX leads with a -68.2% price change compared with -91.8% for ALEC. Alector is the larger company by market cap ($214.4 million vs $183.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | CMPX |
|---|---|---|
| Share price | $1.92 | $1.02 |
| Market cap | $214.38M | $183.69M |
| 1-day change | +6.08% | +2.19% |
| YTD return | +23.08% | -81.01% |
| 1-year return | -37.46% | -71.75% |
| 5-year return | -91.76% | -68.22% |
| EPS (TTM) | $-1.09 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $6.88 |
| 52-week low | $1.09 | $0.829 |
| Distance from 52-week high | -43.53% | -85.17% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +71.88% | +434.31% |
| Average volume | 2.75M | 4.08M |
| Shares outstanding | 111.66M | 180.09M |
| Employees | 103 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALEC has outperformed CMPX by 34.3 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Healthcare · Biotechnology · 103 employees
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Healthcare · Biotechnology · 39 employees
ALEC vs CMPX FAQ
Which is bigger, Alector or Compass Therapeutics?
Alector (ALEC) is larger, with a market capitalization of $214.38M compared with $183.69M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, ALEC or CMPX?
ALEC returned -37.46% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Compass Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.